Evolent Health, Inc (NYSE:EVH)‘s stock had its “buy” rating reiterated by stock analysts at Cantor Fitzgerald in a report released on Thursday. They currently have a $30.00 price target on the technology company’s stock.

The analysts wrote, “3Q17 results. Adjusted 3Q17 revenue of $108.4 million (+80% y/y) came in ahead of FactSet consensus and our estimate of $104 million. The number of lives on the platform was 2.7 million (-4% q/q, +84.7% y/y). The sequential decline was related to churn in Medicaid. Adjusted transformation revenue of $8.2 million increased 6% y/y. Transformation revenue can fluctuate quarter- to-quarter due to the timing of customer contracts and the scope of delivery. Adjusted platform and operations revenue of $100.2 million increased 91% y/ y driven by an increase in the number of lives on the platform. Average PMPM was $12.20 in 3Q17. EVH achieved positive adjusted EBITDA in the quarter.””

Other analysts have also issued reports about the stock. BidaskClub raised shares of Evolent Health from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. SunTrust Banks, Inc. reissued a “buy” rating and issued a $30.00 price target on shares of Evolent Health in a research report on Wednesday, September 20th. Robert W. Baird set a $35.00 price target on shares of Evolent Health and gave the stock a “buy” rating in a research report on Tuesday, August 8th. J P Morgan Chase & Co reissued a “buy” rating on shares of Evolent Health in a research report on Friday, August 18th. Finally, Leerink Swann set a $32.00 price target on shares of Evolent Health and gave the stock a “buy” rating in a research report on Friday, August 18th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $28.70.

Evolent Health (NYSE:EVH) last posted its quarterly earnings data on Monday, August 7th. The technology company reported ($0.13) EPS for the quarter, meeting analysts’ consensus estimates of ($0.13). Evolent Health had a negative net margin of 17.57% and a negative return on equity of 6.44%. The company had revenue of $107.30 million during the quarter, compared to analyst estimates of $104.45 million. During the same period in the prior year, the firm earned ($0.20) earnings per share. The business’s quarterly revenue was up 89.9% on a year-over-year basis.

TRADEMARK VIOLATION WARNING: “Cantor Fitzgerald Reaffirms Buy Rating for Evolent Health, Inc (EVH)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.watchlistnews.com/cantor-fitzgerald-reaffirms-buy-rating-for-evolent-health-inc-evh/1674367.html.

A number of hedge funds have recently made changes to their positions in EVH. Parametric Portfolio Associates LLC acquired a new position in Evolent Health during the first quarter valued at approximately $213,000. American International Group Inc. grew its holdings in Evolent Health by 7.5% during the first quarter. American International Group Inc. now owns 9,403 shares of the technology company’s stock valued at $210,000 after purchasing an additional 653 shares during the last quarter. Vanguard Group Inc. grew its holdings in Evolent Health by 18.1% during the first quarter. Vanguard Group Inc. now owns 2,531,928 shares of the technology company’s stock valued at $56,462,000 after purchasing an additional 388,668 shares during the last quarter. Geode Capital Management LLC grew its holdings in Evolent Health by 3.1% during the first quarter. Geode Capital Management LLC now owns 130,053 shares of the technology company’s stock valued at $2,900,000 after purchasing an additional 3,889 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Evolent Health by 119.7% during the first quarter. Renaissance Technologies LLC now owns 90,300 shares of the technology company’s stock valued at $2,014,000 after purchasing an additional 49,200 shares during the last quarter. Institutional investors own 89.64% of the company’s stock.

About Evolent Health

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Analyst Recommendations for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.